SHMT2 and neoplasm: Interestingly, a few other cancer types, such as some human breast cancers, adrenocortical carcinoma and kidney chromophobe cell carcinoma, also exhibit an increased SHMT2 expression in metastatic tumor tissue during cancer progression [53].